Eamon P Raith1,2,3, Astri M V Luoma1,2, Mark Earl1, Meera Dalal1, Sandra Fairley1, Felicity Fox1, Katharine Hunt1, Charlotte Willett1, Ugan Reddy1,2. 1. Department of Neuroanaesthesia and Neurocritical Care Medicine, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square. 2. Department of Brain Repair and Rehabilitation, Institute of Neurology, University College London, London, UK. 3. Discipline of Acute Care Medicine, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
Abstract
BACKGROUND: The World Health Organisation declared a coronavirus disease 2019 (COVID-19) pandemic on March 11, 2020. Following activation of the UK pandemic response, our institution began planning for admission of COVID-19 patients to the neurointensive care unit (neuro-ICU) to support the local critical care network which risked being rapidly overwhelmed by the high number of cases. This report will detail our experience of repurposing a neuro-ICU for the management of severely ill patients with COVID-19 while retaining capacity for urgent neurosurgical and neurology admissions. METHODS: We conducted a retrospective process analysis of the repurposing of a quaternary level neuro-ICU during the early stages of the COVID-19 pandemic in the United Kingdom. We retrieved demographic data, diagnosis, and outcomes from the electronic health care records of all patients admitted to the ICU between March 1, 2020 and April 30, 2020. Processes for increase in surge capacity, reduction in ICU demand, and staff redeployment and rapid training are reported. RESULTS: Over a 10-day period, total ICU capacity was increased by 21.7% (from 23 to 28 beds) while the capacity to provide mechanical ventilation was increased by 77% (from 13 to 23 beds). There were 30 ICU admissions of 29 COVID-19 patients between March 1 and April 30, 2020; median (range) length of ICU stay was 9.9 (1.3 to 32) days, duration of mechanical ventilation 11 (1 to 27) days, and ICU mortality rate 41.4%. There was a 44% reduction in urgent neurosurgical and neurology admissions compared with the same period in 2019. CONCLUSIONS: It is possible to repurpose a dedicated neuro-ICU for the management of critically ill non-neurological patients during a pandemic response, while maintaining access for urgent neuroscience referrals.
BACKGROUND: The World Health Organisation declared a coronavirus disease 2019 (COVID-19) pandemic on March 11, 2020. Following activation of the UK pandemic response, our institution began planning for admission of COVID-19patients to the neurointensive care unit (neuro-ICU) to support the local critical care network which risked being rapidly overwhelmed by the high number of cases. This report will detail our experience of repurposing a neuro-ICU for the management of severely illpatients with COVID-19 while retaining capacity for urgent neurosurgical and neurology admissions. METHODS: We conducted a retrospective process analysis of the repurposing of a quaternary level neuro-ICU during the early stages of the COVID-19 pandemic in the United Kingdom. We retrieved demographic data, diagnosis, and outcomes from the electronic health care records of all patients admitted to the ICU between March 1, 2020 and April 30, 2020. Processes for increase in surge capacity, reduction in ICU demand, and staff redeployment and rapid training are reported. RESULTS: Over a 10-day period, total ICU capacity was increased by 21.7% (from 23 to 28 beds) while the capacity to provide mechanical ventilation was increased by 77% (from 13 to 23 beds). There were 30 ICU admissions of 29 COVID-19patients between March 1 and April 30, 2020; median (range) length of ICU stay was 9.9 (1.3 to 32) days, duration of mechanical ventilation 11 (1 to 27) days, and ICU mortality rate 41.4%. There was a 44% reduction in urgent neurosurgical and neurology admissions compared with the same period in 2019. CONCLUSIONS: It is possible to repurpose a dedicated neuro-ICU for the management of critically ill non-neurological patients during a pandemic response, while maintaining access for urgent neuroscience referrals.
Authors: Costase Ndayishimiye; Christoph Sowada; Patrycja Dyjach; Agnieszka Stasiak; John Middleton; Henrique Lopes; Katarzyna Dubas-Jakóbczyk Journal: Int J Environ Res Public Health Date: 2022-07-04 Impact factor: 4.614
Authors: Michael Zhang; James Zhou; Benjamin Dirlikov; Tene Cage; Marco Lee; Harminder Singh Journal: J Clin Neurosci Date: 2022-05-02 Impact factor: 2.116
Authors: Deborah R Douglas; David Choi; Hani J Marcus; Will Muirhead; Ugan Reddy; Trudy Stewart; Astri M V Luoma Journal: J Neurosurg Anesthesiol Date: 2021-03-29 Impact factor: 3.969
Authors: Norha Vera San Juan; Sigrún Eyrúnardóttir Clark; Matthew Camilleri; John Paul Jeans; Alexandra Monkhouse; Georgia Chisnall; Cecilia Vindrola-Padros Journal: BMJ Open Date: 2022-01-07 Impact factor: 2.692